Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel versus standard of care in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
NL-OMON56315Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-Hodgkin lymphoma (NHL), mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL) comparing Tisagenlecleucel with Standard of care (2 arms). Primary endpoint: Event-free survival. Started Nov 2019; status: recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
non-Hodgkin lymphoma (NHL)mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON56315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56315.